surmount-1 tirzepatide 15 mg weight loss percent Relationship of early rapid to efficacy and safety of and semaglutide for obesity: SURMOUNT-5 post hoc analysis Dose-equivalence reference based on pivotal

*In a 72-week study of adults without diabetes (SURMOUNT-1), average weight loss was 15.0% (34 lbs) for 5mg, 19.5% (44 lbs) for 10mg, 20.9% (48 lbs) for 15mg, and 3.1% (7 lbs) for placebo

Semaglutide: Target Demographics and Special Considerations Semaglutide is primarily used in adult patients with type 2 diabetes

The lack of awareness (60), paucity of diagnostic tools (60), heterogeneity between patients (26, 60, 529), disbelief from health care workers (60), unpredictable relapses, and multiplicity of symptoms have made it difficult to formulate a treatment for ME/CFS

doi: 10.1016/j.dnarep.2023.103487 138 SinghS

Ingredients that are versatile, familiar, and nutritionally dense, such as chia, naturally fit within this broader direction